Investor Conference Call on Xarelto COMPASS Data at ESC Congress 2017

Monday, August 28, 2017
Start approx. 1:30 p.m. CEST (11:30 a.m. UTC)

Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) have been featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we hosted a conference call for investors and analysts on August 28, 2017.

Investor News on Xarelto COMPASS Data

Dr. Jörg Möller
Head of Global Development at Pharmaceuticals

Dr. Frank Misselwitz
Head of the Therapeutic Area Thrombosis and Hematology

with
Dr. Jörg Möller, Head of Global Development at Pharmaceuticals
Dr. Frank Misselwitz, Head of the Therapeutic Area Thrombosis and Hematology
Oliver Maier, Head of Bayer Investor Relations

Audio recording of the investor conference call
(MP3 format)

You can also play the audio recording on your mobile device.

Presentation Charts
Download PDF collect (947 KB)
Transcript Download PDF collect (64 KB)

Investor News on Xarelto COMPASS Data

Investor News August 27, 2017
Not intended for U.S. and UK Media - Data from COMPASS study, including 27,395 patients, presented at ESC Congress 2017:

Bayer's Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24%

Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone / Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding / This combination regimen demonstrated a substantial improvement in net clinical benefit of 20% more

Services

Current Links

Bayer at ESC Congress 2017
ESC Congress 2017
Xarelto